AG˹ٷ

STOCK TITAN

[8-K] Walgreens Boots Alliance, Inc Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

On 11 July 2025, I-MAB (Nasdaq: IMAB) submitted a Form 6-K to notify investors that it has amended its 15 May 2025 prospectus covering the offer and sale of up to US$21 million in American Depositary Shares (ADSs). Each block of ten ADSs represents twenty-three ordinary shares with a par value of US$0.0001. The prospectus is part of the company’s shelf Registration Statement on Form F-3 (File No. 333-286954).
The filing attaches a Cayman Islands legal opinion from Harney Westwood & Riegels (Exhibit 5.1) together with the corresponding consent (Exhibit 23.1), confirming the validity of the ADSs and underlying ordinary shares. The 6-K states that the information and exhibits are incorporated by reference into the existing Form F-3 and several Form S-8 registration statements covering share-based compensation plans.
No operating or financial results are disclosed. The amendment maintains regulatory compliance and keeps the shelf registration effective, giving I-MAB flexibility to raise up to US$21 million when market conditions permit. While this improves liquidity options, it may also lead to equity dilution for current shareholders if the full amount is issued.

Il 11 luglio 2025, I-MAB (Nasdaq: IMAB) ha presentato un Modulo 6-K per informare gli investitori di aver modificato il prospetto del 15 maggio 2025 relativo all'offerta e vendita fino a 21 milioni di dollari in American Depositary Shares (ADS). Ogni blocco di dieci ADS rappresenta ventitré azioni ordinarie con un valore nominale di 0,0001 dollari USA. Il prospetto fa parte della dichiarazione di registrazione a scaffale della società sul Modulo F-3 (File No. 333-286954).
La documentazione allega un parere legale delle Isole Cayman di Harney Westwood & Riegels (Esibizione 5.1) insieme al relativo consenso (Esibizione 23.1), che conferma la validità delle ADS e delle azioni ordinarie sottostanti. Il 6-K specifica che le informazioni e gli allegati sono incorporati per riferimento nel Modulo F-3 esistente e in diversi moduli di registrazione S-8 relativi a piani di compensazione basati su azioni.
Non vengono divulgati risultati operativi o finanziari. La modifica mantiene la conformità normativa e mantiene valida la registrazione a scaffale, offrendo a I-MAB la flessibilità di raccogliere fino a 21 milioni di dollari quando le condizioni di mercato lo permettono. Sebbene questo migliori le opzioni di liquidità, potrebbe anche comportare una diluizione azionaria per gli azionisti attuali se l’intero importo verrà emesso.

El 11 de julio de 2025, I-MAB (Nasdaq: IMAB) presentó un Formulario 6-K para notificar a los inversores que ha modificado su prospecto del 15 de mayo de 2025 que cubre la oferta y venta de hasta 21 millones de dólares en American Depositary Shares (ADS). Cada bloque de diez ADS representa veintitrés acciones ordinarias con un valor nominal de 0,0001 dólares. El prospecto forma parte de la declaración de registro en estantería de la compañía en el Formulario F-3 (Archivo No. 333-286954).
La presentación incluye una opinión legal de las Islas Caimán de Harney Westwood & Riegels (Exhibición 5.1) junto con el consentimiento correspondiente (Exhibición 23.1), confirmando la validez de las ADS y las acciones ordinarias subyacentes. El 6-K indica que la información y los anexos se incorporan por referencia en el Formulario F-3 existente y en varios formularios de registro S-8 relacionados con planes de compensación basados en acciones.
No se divulgan resultados operativos ni financieros. La enmienda mantiene el cumplimiento regulatorio y mantiene vigente el registro en estantería, dando a I-MAB flexibilidad para recaudar hasta 21 millones de dólares cuando las condiciones del mercado lo permitan. Aunque esto mejora las opciones de liquidez, también puede provocar una dilución accionaria para los accionistas actuales si se emite el monto total.

2025� 7� 11�, I-MAB(Nasdaq: IMAB)� 투자자들에게 2025� 5� 15일자 증권 설명� 수정� 알리� 위해 Form 6-K� 제출했습니다. � 수정은 미국 예탁증서(ADS) 최대 2,100� 달러� 공모 � 판매와 관련된 내용입니�. 10개의 ADS 묶음은 각각 0.0001달러 액면가� 보통� 23주를 나타냅니�. � 증권 설명서는 회사� Form F-3(파일 번호 333-286954) 선반 등록 신고서의 일부입니�.
제출 서류에는 Harney Westwood & Riegels� 케이맨 제도 법률 의견�(증거자료 5.1)와 해당 동의�(증거자료 23.1)가 첨부되어 ADS � 기초 보통주의 유효성을 확인합니�. 6-K 문서에는 해당 정보와 증거자료가 기존 Form F-3 � 주식 기반 보상 계획� 다루� 여러 Form S-8 등록 신고서에 참조� 포함된다� 명시되어 있습니다.
운영 또는 재무 결과� 공개되지 않았습니�. 이번 수정은 규제 준수를 유지하고 선반 등록� 유효하게 하여 시장 상황� 허락� � 최대 2,100� 달러� 조달� � 있는 유연성을 I-MAB� 제공합니�. 이는 유동� 옵션� 개선하지�, 전액 발행 � 기존 주주에게 주식 희석� 발생� � 있습니다.

Le 11 juillet 2025, I-MAB (Nasdaq : IMAB) a soumis un formulaire 6-K pour informer les investisseurs qu’elle a modifié son prospectus du 15 mai 2025 couvrant l’offre et la vente jusqu’� 21 millions de dollars américains en American Depositary Shares (ADS). Chaque bloc de dix ADS représente vingt-trois actions ordinaires d’une valeur nominale de 0,0001 USD. Le prospectus fait partie de la déclaration d’enregistrement sur étagère de la société sur le formulaire F-3 (numéro de dossier 333-286954).
Le dépôt comprend un avis juridique des îles Caïmans de Harney Westwood & Riegels (exposition 5.1) ainsi que le consentement correspondant (exposition 23.1), confirmant la validité des ADS et des actions ordinaires sous-jacentes. Le 6-K précise que les informations et les annexes sont incorporées par référence dans le formulaire F-3 existant et plusieurs déclarations d’enregistrement sur formulaire S-8 couvrant des plans de rémunération en actions.
Aucun résultat opérationnel ou financier n’est divulgué. L’amendement maintient la conformité réglementaire et garde la déclaration d’enregistrement sur étagère en vigueur, offrant à I-MAB la flexibilité de lever jusqu’� 21 millions de dollars lorsque les conditions du marché le permettent. Bien que cela améliore les options de liquidité, cela peut également entraîner une dilution des actions pour les actionnaires actuels si le montant total est émis.

Am 11. Juli 2025 reichte I-MAB (Nasdaq: IMAB) ein Formular 6-K ein, um Investoren darüber zu informieren, dass es seinen Prospekt vom 15. Mai 2025 geändert hat, der das Angebot und den Verkauf von bis zu 21 Millionen US-Dollar in American Depositary Shares (ADS) abdeckt. Jeder Block von zehn ADS repräsentiert dreiundzwanzig Stammaktien mit einem Nennwert von 0,0001 US-Dollar. Der Prospekt ist Teil der Shelf-Registrierungserklärung des Unternehmens auf Formular F-3 (Aktenzeichen 333-286954).
Die Einreichung enthält eine Rechtsgutachten der Kaimaninseln von Harney Westwood & Riegels (Anlage 5.1) zusammen mit der entsprechenden Zustimmung (Anlage 23.1), die die Gültigkeit der ADS und der zugrunde liegenden Stammaktien bestätigt. Im 6-K wird angegeben, dass die Informationen und Anlagen durch Verweis in das bestehende Formular F-3 und mehrere Formular S-8-Registrierungserklärungen aufgenommen werden, die aktienbasierte Vergütungspläne abdecken.
Es werden keine operativen oder finanziellen Ergebnisse offengelegt. Die Änderung gewährleistet die Einhaltung der Vorschriften und hält die Shelf-Registrierung wirksam, wodurch I-MAB die Flexibilität erhält, bis zu 21 Millionen US-Dollar zu beschaffen, wenn die Marktbedingungen dies zulassen. Obwohl dies die Liquiditätsoptionen verbessert, kann es auch zu einer پԱäܲԲ für die aktuellen Aktionäre führen, falls der volle Betrag ausgegeben wird.

Positive
  • Shelf registration remains effective, giving the company flexibility to raise up to US$21 million when opportune.
  • Legal opinion and consent filed, reducing execution risk and demonstrating regulatory compliance.
Negative
  • Potential equity dilution if the full US$21 million ADS offering is executed.
  • Filing offers no operational or earnings information, leaving investors without insight into current performance or cash runway.

Insights

TL;DR � Neutral: keeps capital window open, modest dilution risk.

The 6-K merely updates legal documentation for an existing Form F-3. Because the maximum raise is capped at US$21 million, the potential dilution is limited relative to large biotech financings, yet meaningful for smaller-cap companies. The attached legal opinion removes an execution hurdle, signalling readiness to issue shares quickly if funding is needed. Absent earnings data, credit metrics or pipeline updates, the filing is administratively important but not fundamentally transformative. Overall impact on valuation is neutral unless or until the company actually sells ADSs.

TL;DR � Slight downside due to dilution overhang.

Investors must now factor in issuance of up to US$21 million in new ADSs—effectively expanding the free float and exerting downward pressure on share price until the offering clears. As no partnership cash or milestone revenue is disclosed, the raise appears intended for general corporate purposes, hinting at ongoing cash burn typical of clinical-stage biotech. Still, the modest size limits balance-sheet transformation. The filing is therefore modestly negative but not catastrophic.

Il 11 luglio 2025, I-MAB (Nasdaq: IMAB) ha presentato un Modulo 6-K per informare gli investitori di aver modificato il prospetto del 15 maggio 2025 relativo all'offerta e vendita fino a 21 milioni di dollari in American Depositary Shares (ADS). Ogni blocco di dieci ADS rappresenta ventitré azioni ordinarie con un valore nominale di 0,0001 dollari USA. Il prospetto fa parte della dichiarazione di registrazione a scaffale della società sul Modulo F-3 (File No. 333-286954).
La documentazione allega un parere legale delle Isole Cayman di Harney Westwood & Riegels (Esibizione 5.1) insieme al relativo consenso (Esibizione 23.1), che conferma la validità delle ADS e delle azioni ordinarie sottostanti. Il 6-K specifica che le informazioni e gli allegati sono incorporati per riferimento nel Modulo F-3 esistente e in diversi moduli di registrazione S-8 relativi a piani di compensazione basati su azioni.
Non vengono divulgati risultati operativi o finanziari. La modifica mantiene la conformità normativa e mantiene valida la registrazione a scaffale, offrendo a I-MAB la flessibilità di raccogliere fino a 21 milioni di dollari quando le condizioni di mercato lo permettono. Sebbene questo migliori le opzioni di liquidità, potrebbe anche comportare una diluizione azionaria per gli azionisti attuali se l’intero importo verrà emesso.

El 11 de julio de 2025, I-MAB (Nasdaq: IMAB) presentó un Formulario 6-K para notificar a los inversores que ha modificado su prospecto del 15 de mayo de 2025 que cubre la oferta y venta de hasta 21 millones de dólares en American Depositary Shares (ADS). Cada bloque de diez ADS representa veintitrés acciones ordinarias con un valor nominal de 0,0001 dólares. El prospecto forma parte de la declaración de registro en estantería de la compañía en el Formulario F-3 (Archivo No. 333-286954).
La presentación incluye una opinión legal de las Islas Caimán de Harney Westwood & Riegels (Exhibición 5.1) junto con el consentimiento correspondiente (Exhibición 23.1), confirmando la validez de las ADS y las acciones ordinarias subyacentes. El 6-K indica que la información y los anexos se incorporan por referencia en el Formulario F-3 existente y en varios formularios de registro S-8 relacionados con planes de compensación basados en acciones.
No se divulgan resultados operativos ni financieros. La enmienda mantiene el cumplimiento regulatorio y mantiene vigente el registro en estantería, dando a I-MAB flexibilidad para recaudar hasta 21 millones de dólares cuando las condiciones del mercado lo permitan. Aunque esto mejora las opciones de liquidez, también puede provocar una dilución accionaria para los accionistas actuales si se emite el monto total.

2025� 7� 11�, I-MAB(Nasdaq: IMAB)� 투자자들에게 2025� 5� 15일자 증권 설명� 수정� 알리� 위해 Form 6-K� 제출했습니다. � 수정은 미국 예탁증서(ADS) 최대 2,100� 달러� 공모 � 판매와 관련된 내용입니�. 10개의 ADS 묶음은 각각 0.0001달러 액면가� 보통� 23주를 나타냅니�. � 증권 설명서는 회사� Form F-3(파일 번호 333-286954) 선반 등록 신고서의 일부입니�.
제출 서류에는 Harney Westwood & Riegels� 케이맨 제도 법률 의견�(증거자료 5.1)와 해당 동의�(증거자료 23.1)가 첨부되어 ADS � 기초 보통주의 유효성을 확인합니�. 6-K 문서에는 해당 정보와 증거자료가 기존 Form F-3 � 주식 기반 보상 계획� 다루� 여러 Form S-8 등록 신고서에 참조� 포함된다� 명시되어 있습니다.
운영 또는 재무 결과� 공개되지 않았습니�. 이번 수정은 규제 준수를 유지하고 선반 등록� 유효하게 하여 시장 상황� 허락� � 최대 2,100� 달러� 조달� � 있는 유연성을 I-MAB� 제공합니�. 이는 유동� 옵션� 개선하지�, 전액 발행 � 기존 주주에게 주식 희석� 발생� � 있습니다.

Le 11 juillet 2025, I-MAB (Nasdaq : IMAB) a soumis un formulaire 6-K pour informer les investisseurs qu’elle a modifié son prospectus du 15 mai 2025 couvrant l’offre et la vente jusqu’� 21 millions de dollars américains en American Depositary Shares (ADS). Chaque bloc de dix ADS représente vingt-trois actions ordinaires d’une valeur nominale de 0,0001 USD. Le prospectus fait partie de la déclaration d’enregistrement sur étagère de la société sur le formulaire F-3 (numéro de dossier 333-286954).
Le dépôt comprend un avis juridique des îles Caïmans de Harney Westwood & Riegels (exposition 5.1) ainsi que le consentement correspondant (exposition 23.1), confirmant la validité des ADS et des actions ordinaires sous-jacentes. Le 6-K précise que les informations et les annexes sont incorporées par référence dans le formulaire F-3 existant et plusieurs déclarations d’enregistrement sur formulaire S-8 couvrant des plans de rémunération en actions.
Aucun résultat opérationnel ou financier n’est divulgué. L’amendement maintient la conformité réglementaire et garde la déclaration d’enregistrement sur étagère en vigueur, offrant à I-MAB la flexibilité de lever jusqu’� 21 millions de dollars lorsque les conditions du marché le permettent. Bien que cela améliore les options de liquidité, cela peut également entraîner une dilution des actions pour les actionnaires actuels si le montant total est émis.

Am 11. Juli 2025 reichte I-MAB (Nasdaq: IMAB) ein Formular 6-K ein, um Investoren darüber zu informieren, dass es seinen Prospekt vom 15. Mai 2025 geändert hat, der das Angebot und den Verkauf von bis zu 21 Millionen US-Dollar in American Depositary Shares (ADS) abdeckt. Jeder Block von zehn ADS repräsentiert dreiundzwanzig Stammaktien mit einem Nennwert von 0,0001 US-Dollar. Der Prospekt ist Teil der Shelf-Registrierungserklärung des Unternehmens auf Formular F-3 (Aktenzeichen 333-286954).
Die Einreichung enthält eine Rechtsgutachten der Kaimaninseln von Harney Westwood & Riegels (Anlage 5.1) zusammen mit der entsprechenden Zustimmung (Anlage 23.1), die die Gültigkeit der ADS und der zugrunde liegenden Stammaktien bestätigt. Im 6-K wird angegeben, dass die Informationen und Anlagen durch Verweis in das bestehende Formular F-3 und mehrere Formular S-8-Registrierungserklärungen aufgenommen werden, die aktienbasierte Vergütungspläne abdecken.
Es werden keine operativen oder finanziellen Ergebnisse offengelegt. Die Änderung gewährleistet die Einhaltung der Vorschriften und hält die Shelf-Registrierung wirksam, wodurch I-MAB die Flexibilität erhält, bis zu 21 Millionen US-Dollar zu beschaffen, wenn die Marktbedingungen dies zulassen. Obwohl dies die Liquiditätsoptionen verbessert, kann es auch zu einer پԱäܲԲ für die aktuellen Aktionäre führen, falls der volle Betrag ausgegeben wird.

false 0001618921 0001618921 2025-07-11 2025-07-11 0001618921 us-gaap:CommonStockMember 2025-07-11 2025-07-11 0001618921 wba:M3.600WalgreensBootsAllianceInc.NotesDue20252Member 2025-07-11 2025-07-11 0001618921 wba:M2.125WalgreensBootsAllianceInc.NotesDue20261Member 2025-07-11 2025-07-11
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 11, 2025

 

 

WALGREENS BOOTS ALLIANCE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36759   47-1758322
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification Number)

 

108 Wilmot Road, Deerfield, Illinois   60015
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (847) 315-3700

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.01 par value   WBA   The Nasdaq Stock Market LLC
3.600% Walgreens Boots Alliance, Inc. notes due 2025   WBA25   The Nasdaq Stock Market LLC
2.125% Walgreens Boots Alliance, Inc. notes due 2026   WBA26   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 5.07.

Submission of Matters to a Vote of Security Holders.

As previously disclosed, on March 6, 2025, Walgreens Boots Alliance, Inc., a Delaware corporation (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Blazing Star Parent, LLC, a Delaware limited liability company (“Parent”), Blazing Star Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the other affiliates of Parent named therein (collectively, together with Parent and Merger Sub, the “Parent Entities”), pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will be merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Parent (the “Merger”). As a result of the Merger, the Company will cease to be a publicly traded company.

On July 11, 2025, the Company held a special meeting of stockholders (the “Special Meeting”) to consider certain proposals related to the Merger Agreement.

As of June 6, 2025, the record date (the “Record Date”) for the Special Meeting, there were 865,560,675 shares of the common stock of the Company, par value $0.01 per share (“Company Common Stock”), outstanding, each of which was entitled to one vote on each matter considered at the Special Meeting. As of the Record Date, there were 717,727,706 shares of Company Common Stock held by holders other than Stefano Pessina, John Lederer, Parent and any of their respective affiliates (the “Unaffiliated Stockholders”). A total of 648,219,746 shares of Company Common Stock, representing approximately 74.89% of the voting power of the outstanding shares of the Company’s Common Stock entitled to vote, were present or represented by proxy at the Special Meeting, constituting a quorum to conduct business.

The Special Meeting was held to consider the following proposals:

 

  1.

Merger Agreement Proposal. A proposal to adopt the Merger Agreement, pursuant to which, subject to the terms and conditions set forth therein and among other things, Merger Sub will be merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Parent (the “Merger Agreement Proposal”).

 

  2.

Adjournment Proposal. A proposal to adjourn the Special Meeting, from time to time, to a later date or dates if necessary or appropriate, including adjournments to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Merger Agreement Proposal (the “Adjournment Proposal”).

 

  3.

Merger-Related Compensation Proposal. A proposal to approve, by a nonbinding, advisory vote, certain compensation that may become payable to the Company’s named executive officers in connection with the completion of the Merger (the “Merger-Related Compensation Proposal”).

Each proposal is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 6, 2025 and first mailed to the Company’s stockholders on June 6, 2025. The Merger Agreement and the Merger-Related Compensation Proposal were each approved by the requisite vote of the Company’s stockholders. The final voting results for each proposal are described below.

The Merger Agreement Proposal

Approval of the proposal to adopt the Merger Agreement required both the affirmative vote of (i) the holders of a majority of the outstanding shares of Company Common Stock entitled to vote on such matter at the Special Meeting (the “Majority of the Outstanding Shares”) and (ii) the holders of a majority of the outstanding shares of Company Common Stock held by the Unaffiliated Stockholders cast on such matter at the Special Meeting (the “Majority of the Unaffiliated Shares Cast”). A total of 500,386,777 shares of Company Common Stock held by the Unaffiliated Stockholders were cast on this matter at the Special Meeting.

 

     For      Against      Abstain  

Majority of the Outstanding Shares

     626,190,387        20,140,186        1,889,173  

Majority of the Unaffiliated Shares Cast

     478,357,418        20,140,186        1,889,173  

The Merger Agreement was approved by the requisite votes of the Company’s stockholders.

 

2


The Merger-Related Compensation Proposal

Approval on a nonbinding advisory basis of the Merger-Related Compensation Proposal required the affirmative vote of a majority of the shares of Company Common Stock present in person or by proxy at the Special Meeting and entitled to vote on the Merger-Related Compensation Proposal.

 

For    Against    Abstain
608,730,038    34,916,603    4,573,105

The Merger-Related Compensation Proposal was approved on a nonbinding advisory basis.

In light of the approval of the Merger Agreement Proposal, the Adjournment Proposal was rendered moot and was not presented at the Special Meeting. There were no recorded broker non-votes.

 

Item 8.01.

Other Events.

On July 11, 2025, the Company issued a press release announcing the preliminary results of the Special Meeting. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

 

(d)

Exhibits

 

Exhibit

  

Description

99.1    Press Release of Walgreens Boots Alliance, Inc. dated July 11, 2025
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

3


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  WALGREENS BOOTS ALLIANCE, INC.
Date: July 11, 2025     By:  

/s/ Lanesha Minnix

    Name: Lanesha Minnix
    Title:Executive Vice President, Global Chief Legal Officer and Corporate Secretary

 

4

FAQ

How much capital can I-MAB (IMAB) raise under the amended prospectus?

The prospectus amendment covers the sale of up to US$21 million in ADSs.

What does each I-MAB ADS represent?

Each 10 ADSs represent 23 ordinary shares with a par value of US$0.0001 per share.

Which registration statement does the amended prospectus belong to?

It is part of I-MAB’s Form F-3 shelf registration (File No. 333-286954).

What legal documents were filed with the Form 6-K?

Exhibit 5.1 is the opinion of Harney Westwood & Riegels; Exhibit 23.1 is their consent, included within Exhibit 5.1.

Will the amended prospectus information affect other I-MAB filings?

Yes. The 6-K states the information is incorporated by reference into the existing Form F-3 and several Form S-8 filings.
Walgreen Boots

NASDAQ:WBA

WBA Rankings

WBA Latest News

WBA Latest SEC Filings

WBA Stock Data

9.93B
713.71M
17.47%
63.53%
7.29%
Pharmaceutical Retailers
Retail-drug Stores and Proprietary Stores
United States
DEERFIELD